Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus
Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix® recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix®. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-α in the Cervarix® groups versus the Gardasil® groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil® recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix® vaccinations. Cervarix® and Gardasil® are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix® after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 10(2014), 12 vom: 08., Seite 3446-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herrin, Douglas M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.10.2015 Date Revised 13.11.2018 published: Print ClinicalTrials.gov: NCT01132859 Citation Status MEDLINE |
|---|
| doi: |
10.4161/hv.34408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244365784 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244365784 | ||
| 003 | DE-627 | ||
| 005 | 20231226191703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4161/hv.34408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0814.xml |
| 035 | |a (DE-627)NLM244365784 | ||
| 035 | |a (NLM)25483691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herrin, Douglas M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2015 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01132859 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules per manufacturer's recommendations, and analyzed the humoral immune response, T cell response, and circulating plasma cytokine levels in response to vaccination. Cervarix® recipients had higher anti-HPV-16 antibody and neutralization titers at month 7, and elevated anti-HPV-18 antibody and neutralization titers at months 7 and 12. Antibody avidity was similar for the 2 vaccines. HPV-31 was the only phylogenetically related non-vaccine HPV type, for which there is evidence of cross-protection, to be cross-neutralized and only in response to Cervarix®. Comparing CD4+ T cell cytokine responses at month 12, there was a trend of increased levels of IL-2 and TNF-α in the Cervarix® groups versus the Gardasil® groups that was consistent across all 4 tested HPV types (16/18/33/45). Elevated levels of circulating plasma cytokine/chemokines were observed post first vaccination in Gardasil® recipients and proinflammatory cytokines were elevated following 1st and 3rd Cervarix® vaccinations. Cervarix® and Gardasil® are both highly immunogenic vaccines. Higher antibody levels and CD4 T cell responses were achieved with Cervarix® after 3 doses, although similar affinity maturation was measured for the 2 vaccines. The clinical implications of the differences in immune responses are unknown | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a adaptive immunity | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a human papillomavirus vaccine | |
| 650 | 4 | |a immune signatures | |
| 650 | 4 | |a innate immunity | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Chemokines |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 |2 NLM | |
| 650 | 7 | |a Papillomavirus Vaccines |2 NLM | |
| 650 | 7 | |a human papillomavirus vaccine, L1 type 16, 18 |2 NLM | |
| 700 | 1 | |a Coates, Emily E |e verfasserin |4 aut | |
| 700 | 1 | |a Costner, Pamela J |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Troy J |e verfasserin |4 aut | |
| 700 | 1 | |a Nason, Martha C |e verfasserin |4 aut | |
| 700 | 1 | |a Saharia, Kapil K |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Yuanji |e verfasserin |4 aut | |
| 700 | 1 | |a Sarwar, Uzma N |e verfasserin |4 aut | |
| 700 | 1 | |a Holman, Lasonji |e verfasserin |4 aut | |
| 700 | 1 | |a Yamshchikov, Galina |e verfasserin |4 aut | |
| 700 | 1 | |a Koup, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Yuk Ying S |e verfasserin |4 aut | |
| 700 | 1 | |a Seder, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Schiller, John T |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Barney S |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Ligia A |e verfasserin |4 aut | |
| 700 | 1 | |a Ledgerwood, Julie E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 10(2014), 12 vom: 08., Seite 3446-54 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2014 |g number:12 |g day:08 |g pages:3446-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4161/hv.34408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2014 |e 12 |b 08 |h 3446-54 | ||